Arrhythmias & electrophysiology
Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis
Main finding · AF recurrenceResult — go to the resultHazard ratio 0.82 95% CI 0.76–0.88Authors' conclusion
In a large real-world cohort of obese patients undergoing catheter ablation for AF, GLP-1RA therapy was associated with lower risks of AF recurrence, progression to permanent AF, cardiovascular hospitalizations, and mortality.
Study context
- Population
- Obese adults (BMI >30 kg/m²) undergoing atrial fibrillation (AF) ablation, TriNetX network, January 2015–January 20251:1 matched cohort
- Participants
- 3,350 vs 3,350
- Exposure
- GLP-1RA use vs no GLP-1RA use
- GLP-1RA usersn = 3,350
- Nonusersn = 3,350reference
- Outcome
- AF recurrence after catheter ablation
- Follow-up
- Median 2 years (IQR 0.8-3.2)
Methodological detailspropensity-score matched, multicentre
- Propensity-score matched
- Multicentre
Main finding
AF recurrence · median follow-up 2 years
Hazard ratio
0.82
95% CI 0.76–0.88
P < 0.0001
By group
GLP-1RA usersvs Nonusers
HR 0.82 (95% CI 0.76–0.88); P < 0.0001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | GLP-1RA users | Nonusers | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Progression to permanent AF · median follow-up 2 yearsPropensity-score matched | 3.16% | 3.38% | 0.77 (0.63–0.93) | P = 0.01 | |
| 0.512Hazard ratio (log scale) |
All-cause mortality · median follow-up 2 years
- Lower risk of all-cause mortality with GLP-1RA vs no GLP-1RA: HR
- 0.73 (0.59-0.91); P=0.01 (95% CI)
- Propensity-score matched
HF hospitalization · median follow-up 2 years
- Lower HF hospitalization with GLP-1RA use vs no GLP-1RA: HR
- 0.80 (0.71-0.90); P<0.0001 (95% CI)
- Propensity-score matched
CV hospitalizations · median follow-up 2 years
- Lower CV hospitalizations with GLP-1RA use vs no GLP-1RA: HR
- 0.85 (0.77-0.93); P=0.001 (95% CI)
- Propensity-score matched
Redo ablation
- No significant difference for redo ablation
Original publication
Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis. Circ Arrhythm Electrophysiol. Published 25 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →